eMed is a digital health innovator and proud NHS partner. We provide the clinical and digital infrastructure to deliver GLP-1 therapies safely, equitably and sustainably — aligned with the 10 Year Health Plan's shift from hospital to community, analogue to digital, and treatment to prevention.
Speak to our NHS team → nhs@emed.com · Typical response within one working day
Rates continue to rise, deprivation deepens the gap, and the downstream cost to the NHS is substantial — placing obesity at the centre of the long-term fiscal and clinical sustainability debate.
The 10 Year Health Plan commits to faster NHS access to GLP-1 therapies. But funding hasn't kept pace with demand, leaving many ICBs unable to commission at scale.
eMed closes both gaps. We combine clinician-led delivery with integrated medication management — helping systems control therapy costs while widening equitable access within existing budgets.
Fit for the Future sets out three foundational shifts for the NHS. A digital model of care for weight loss — done properly — delivers against all three at once.
Specialist obesity care has historically sat in Tier 3 and Tier 4 hospital services. Our digital-first model brings clinician-led weight management closer to home — accessible from anywhere, supported 24/7, and designed to take pressure off acute pathways.
The Plan commits to expanding digitally-enabled weight management pathways and digital-only delivery models. eMed already operates one of the UK's largest digital-first primary care practices, with the clinical governance, data infrastructure and real-world evidence to support the shift.
Obesity drives type 2 diabetes, cardiovascular disease, cancer and more. By delivering safe, sustained weight loss at population scale, a digital model of care reduces downstream demand on the system it sits within — the definition of upstream prevention.
Our approach drives high patient adherence, improves outcomes at population scale, and reduces the downstream burden of obesity-related conditions. It is designed to fit within NHS pathways, not around them.
Measurable outcomes, through weight, metabolic changes, behavioural change and cardiovascular risk reduction.
eMed is conducting one of the largest real-world studies of GLP-1 treatment in women, in collaboration with University College London and led by Professor John Deanfield. Full findings will be shared on publication.
A dedicated session for commissioners, ICB leaders and clinical decision-makers. Places are limited.
Register for the webinar → Free · Approximately 45 minutes · Recording available on requestWhether you're an ICB, Trust, NHS England team or policy partner, our NHS team can walk you through the clinical model, the evidence, and how we'd work with you in practice.
Speak to our NHS team nhs@emed.com
